Longevity Technology

Biogen is diversifying its portfolio across neurology and rare diseases to build long-term recurring revenue. The strategy focuses on high-value biologic therapies for central nervous system disorders, including multiple sclerosis and spinal muscular atrophy, and on specialty medicines for genetically defined rare diseases.

Leerink initiated coverage of Altimmune, Inc. on 22 June 2026, assigning an Outperform rating and a $10 price target and identifying the firm as an attractive play in the mash therapeutics market. The move followed 48-week results from Altimmune’s IMPACT Phase 2b trial announced in May 2026, evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis.

Longevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.

NKGen Biotech will present its lead investigational program, Troculeucel, at the BIOCHINA Global Forum in Seoul on 10 July 2026. The company’s chairman and chief executive officer, Paul Y. Song, M.D., is scheduled to speak 10 July at 13:40–14:00 KST (12:40–1:00 AM ET) on the use of Troculeucel, described by the company as a cryopreserved enhanced autologous natural killer cell therapy, for neurodegenerative diseases.

United Therapeutics has acquired Thymmune Therapeutics, a privately held preclinical biotechnology company developing regenerative thymic cell therapies, in a transaction announced on 2 July 2026. The agreement provides $140 million in cash, subject to post-closing adjustments, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.

Sky Labs presented its ring-type cuffless blood pressure monitor, CART BP pro, at the 9th Digital Biomarkers in Clinical Trials Summit in Basel, Switzerland, the company announced on 3 July 2026. According to the company, it showcased the device as a data platform for drug clinical trials and Real-World Evidence collection and said the platform has been adopted for a large-scale cohort study managed by the National Institutes of Health under the Korea Disease Control and Prevention Agency.

Modern hospitals have monitors, alarms, dashboards and devices constantly generating new readings, so no shortage of information. Yet one of healthcare’s biggest challenges isn’t collecting more data, but making sense of it. Too many alerts can overwhelm clinicians rather than help them. The phenomenon has a name: “alarm fatigue.” When every beep demands attention, distinguishing a genuine emergency from background noise becomes increasingly difficult.

In drug development, sometimes, the biggest story is what regulators are willing to do with the evidence. AI-powered, clinical-stage biopharma company BPGbio has revealed new findings supporting BPM31510, its investigational therapy for primary CoQ10 deficiency (PCQD), while revealing something equally notable: following a Type C meeting with the US Food and Drug Administration (FDA), the company is preparing to move into a pivotal Phase 3 trial [1].

Peptides have become one of the most closely watched areas in longevity medicine, attracting growing interest from researchers, clinicians and consumers alike. Yet despite their popularity, the evidence supporting many peptide interventions remains uneven – ranging from established clinical applications to early-stage experimental research and mechanistic hypotheses.

A new chapter for consumer longevity? For a company synonymous with premium longevity programs, a $595 annual membership is a bold statement. Fountain Life has built its reputation around comprehensive preventive health programs that use advanced diagnostics to uncover disease risks long before symptoms appear. Those services have largely appealed to affluent consumers willing to spend thousands (sometimes tens of thousands) of dollars for an in-depth picture of their health.